Lab coats are finally getting their Wall Street moment again. The SPDR S&P Biotech ETF has climbed 19% over the past three months, crushing the S&P 500’s modest gain during the same stretch. Yet the sector remains roughly 40% below its pandemic-era peak and trades slightly under historical enterprise value-to-sales averages — making it one of the market’s rare bargains.

• M&A activity has accelerated, with global biotech deals tracking toward $179B annually — the strongest since 2019, according to Stifel’s Tim Opler.
• FDA approvals have restored steady confidence since April, while the 2020–21 biotech bubble has deflated, with firms trading below cash value falling from 200 to about 50.

Science meets sentiment: Clinical trials in once-disappointing fields like gene editing and gene therapy are yielding promising results, fueling optimism and drawing in new capital. Meanwhile, Big Pharma’s appetite for acquisitions is growing as patent cliffs approach, reflected in deals such as Pfizer’sPFE

purchase of Metsera and Novo Nordisk’sNVO

acquisition of Akero Therapeutics. Still, for the first time in years, optimism and innovation are moving in sync — and with investors chasing lower-risk opportunities, biotech’s rebound may still have room to run.